|
IQVIA™ Real-World Insights Bibliography
| Empagliflozin cardiovascular and renal effectiveness and safety compared to dipeptidyl peptidase-4 inhibitors across 11 countries in Europe and Asia: Results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study |
| Author(s): Avraham Karasik (1), Stefanie Lanzinger (2,3), Elise Chia-Hui Tan (4), Daisuke Yabe (5,6,7 8), Dae Jung Kim (9), Wayne H-H Sheu (10), Cheli Melzer-Cohen (1), Reinhard W. Holl (2), Kyoung-Hwa Ha (9), Kamlesh Khunti (11), Francesco Zaccardi (11), Anuradhaa Subramanian (12), Krishnarajah Nirantharakumar (12,13,14), Thomas Nyström (15), Leo Niskanen (16), Majken Linnemann Jensen (17), Fabian Hoti (18), Riho Klement (19), Anouk Déruaz-Luyet (20), Moe H.Kyaw (21), Lisette Koeneman (22), Dorte Vistisen (23, 24) Bendix Carstensen (23), Sigrun Halvorsen (25), Gisle Langslet (26), Soulmaz Fazeli Farsani (20), Elisabetta Patorno (27), Júlio Núñez (28), EMPRISE Europe and Asia Study Group
|
| Affiliations(s): "1
Maccabi Institute for Research and Innovation Center, Tel Aviv University, Tel Aviv, Israel
2
Institute for Epidemiology and Medical Biometry, ZIBMT, Ulm University, Ulm, Germany
3
German Centre for Diabetes Research (DZD), München-Neuherberg, Germany
4
Department of Health Service Administration, China Medical University, Taichung, Taiwan
5
Yutaka Seino Distinguished Center for Diabetes Research, Kansai Electric Power Medical Research Institute, Kyoto, Japan
6
Department of Diabetes, Metabolism and Endocrinology/Department of Rheumatology and Clinical Immunology, Gifu University Graduate School of Medicine, Gifu, Japan
7
Center for Healthcare Information Technology, Tokai National Higher Education and Research System, Nagoya, Japan
8
Preemptive Food Research Center, Gifu University Institute for Advanced Study, Gifu, Japan
9
Department of Endocrinology and Metabolism, Ajou University School of Medicine, Suwon, South Korea
10
Division of Endocrinology and Metabolism, Taipei Veterans General Hospital, Taipei, Taiwan
11
Leicester Real World Evidence Unit, Leicester Diabetes Centre, University of Leicester, Leicester, UK
12
Institute of Applied Health Research, University of Birmingham, Birmingham, UK
13
Midlands Health Data Research UK, Birmingham, UK
14
DEMAND Hub, University of Birmingham, Birmingham, UK
15
Department of Clinical Science and Education, Södersjukhuset, Karolinska Institutet, Sweden
16
Päijät-Häme Joint Authority for Health and Wellbeing, Päijät-Häme Central Hospital, Lahti Finland and University of Eastern Finland, Kuopio, Finland
17
IQVIA Solutions Denmark A/S, Copenhagen, Denmark
18
IQVIA, Espoo, Finland
19
IQVIA, Tartu, Estonia
20
Boehringer Ingelheim International GmbH, Ingelheim, Germany
21
Boehringer Ingelheim International GmbH, US
22
Lilly Deutschland GmbH, Bad Homburg, Germany
23
Steno Diabetes Center Copenhagen, Herlev, Denmark
24
Department of Public Health, University of Copenhagen, Copenhagen, Denmark
25
Department of Cardiology, Oslo University Hospital Ullevål, and University of Oslo, Oslo, Norway
26
Lipid Clinic, Department of Endocrinology, Morbid Obesity and Preventive Medicine, Oslo University Hospital, Oslo, Norway
27
Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, and Harvard Medical School, Boston, Massachusetts, USA
28
Department of Cardiology, Hospital Clínico Universitario de Valencia, INCLIVA, Universidad de Valencia, CIBER Cardiovascular, Valencia, Spain" |
Publication(s): "Diabetes & Metabolism. 2023 Jan; 101418; ISSN 1262-3636
Virtual Conference: American Diabetes Association, 25-29 June 2021 and EASD 27 September -01 October"
|
| Document Type(s): Article, |
| Countries: Denmark, Finland, Germany, Norway, Spain, Sweden, UK, |
| Click here for the abstract |
C:
Y: |
Cardiovascular disease, Diabetes, Drug safety, Drug Utlization Study,
2023 |
|
L:
A: |
English
Clinical setting: hospital, Clinical setting: Primary care, |
|
 |
| |
| |
| The CLARION study design and status update: a long-term, registry-based study evaluating adverse events of special interest in patients with relapsing multiple sclerosis newly started on cladribine tablets |
| Author(s): Helmut Butzkueven 1 2, Nicholas Moore 3, Aida Aydemir 4, Jaak Sõnajalg 5, Irene Bezemer 6, Pasi Korhonen 7, Meritxell Sabidó 8, CLARION Study Group |
| Affiliations(s): 1Department of Neuroscience, Central Clinical School, Monash University, Melbourne, Australia.
2The Alfred Hospital, Melbourne, Australia.
3Bordeaux PharmacoEpi (BPE), Université de Bordeaux, Bordeaux, France.
4Global Biostatistics, EMD Serono Research & Development Institute, Inc, Billerica, MA, USA (an affiliate of Merck KGaA).
5Global Database Studies, IQVIA, Tartu, Estonia.
6Global Epidemiology and Outcomes Research, IQVIA, Amsterdam, The Netherlands.
7IQVIA (former EPID Research), Espoo, Finland.
8Global Epidemiology, Merck Healthcare KGaA, Darmstadt, Germany. |
Publication(s): Current Medical Research and Opinion, DOI: 10.1080/03007995.2022.2059977
|
| Document Type(s): Article, |
| Countries: Australia, Denmark, Finland, Germany, Norway, Sweden, Switzerland, Turkey, |
| Click here for the abstract |
C:
Y: |
Drug safety, Neurological disorders,
2022 |
|
L:
A: |
English
clinical setting: Secondary care, Epidemiological study, Observational study, Population Based Study, Retrospective database analysis, |
|
|
| |
| |
| A Survey Among Health Care Professionals to Assess Their Knowledge and Understanding on Darzalex® (Daratumumab)
Educational Materials Regarding the Risk of Interference for Blood Typing in 12 European Countries |
| Author(s): Mathieu Rosé, Intissar Bourahla, Alessandro Ghiddi, Assem Al-Akabawi, Edmond Chan, Massoud Toussi |
| Affiliations(s): IQVIA, Courbevoie, France;
Janssen EMEA, Medical Affairs, Italy;
Janssen EMEA, Medical Affairs, UK |
Publication(s): Presented at ISPE?s 35th International Conference on Pharmacoepidemiology and Therapeutic Risk
Management (ICPE 2019), August 24?28, 2019 at the Pennsylvania Convention Center, Philadelphia, PA, USA.
|
| Document Type(s): Poster, |
| Countries: Austria, Czech, Denmark, Finland, France, Germany, Hungary, Norway, Slovakia, Spain, Sweden, Switzerland, |
| Click here for the abstract |
C:
Y: |
Hematology, Oncology,
2019 |
|
L:
A: |
English
Public Health, Survey research, |
|
|
| |
| |
| No increased risk of spontaneous abortion and ectopic pregnancy after exposure to interferon-beta prior to or during pregnancy: Results from register-based Nordic study among women with MS |
| Author(s): R. Juuti1, K. M. Hakkarainen 1, S. Burkill 2, Y. Geissbuehler 3, M. Sabidó 4, C. Popescu 5, A. Adamo 6, J. Hillert 2, S. Cnattingius 2, M. Artama 7, A. Verkkoniemi-Ahola 8, K.-M. Myhr 9, J. Mehtälä 1, S. Bahmanyar 2, S. Montgomery 2,10, P. Korhonen 1 and the European Interferon Beta Pregnancy Study Group |
| Affiliations(s): 1StatFinn-EPID Research, Espoo, Finland |
Publication(s): EAN, Oslo, Norway, June 29-2 July, 2019
|
| Document Type(s): Oral presentation, |
| Countries: Finland, Germany, Norway, Sweden, Switzerland, UK, |
| Click here for the abstract |
C:
Y: |
Neurological disorders,
2019 |
|
L:
A: |
English
Epidemiological study, Population Based Study, Retrospective database analysis, |
|
|
| |
| |
| Assessing the Outcomes for Orphan Status or Accelerated Assessment EMA Approved Medicines: A Comparison of Health Technology Assessment in Denmark, Finland, Norway and Sweden |
| Author(s): Falla, Edel; Pitcher, Ashley; Acs, Annabel; Heller, Vincent; Zhang, Rongrong |
| Affiliations(s): IQVIA, Real-World Insights, London, LON, UK
IQVIA, Real-World Insights, Copenhagen, Denmark
IQVIA, Real-World Insights, Copenhagen, Denmark
IQVIA, Real-World Insights, Solna, AB, Sweden
IQVIA, Real-World Insights, Stockholm, Sweden |
Publication(s): ISPOR Europe 2019, November 5, 2019, Copenhagen, Denmark
|
| Document Type(s): Poster, |
| Countries: Denmark, Finland, Nordic, Norway, Sweden, |
| Click here for the abstract |
C:
Y: |
Comparative Effectiveness & Health Technology Assessment,
2019 |
|
L:
A: |
English
Review, |
|
|
| |
| |
| Patient and caregiver indirect costs after acute cardiovascular events in Europe. |
| Author(s): Sidelnikov E1, Gerlier L2, Kutikova L1, Amarenco P3, Kotseva K4, Annemans L5 |
| Affiliations(s): 1 Amgen (Europe) GmbH, Zug, Switzerland 2 IQVIA, Zaventem, Belgium 3 Paris-Diderot-Sorbonne University, Paris, France 4 National Heart & Lung Institute, Imperial College London, London, UK 5 Ghent University, Ghent, Belgium |
Publication(s): ISPOR 21st Annual European Congress, 2018, November 10-14, Barcelona, Spain
|
| Document Type(s): Oral presentation, |
| Countries: Austria, Bulgaria, Croatia, Czech, Denmark, Finland, Germany, Greece, Italy, Norway, Romania, Slovakia, Slovenia, |
| Click here for the abstract |
C:
Y: |
Cardiovascular disease, Health economics,
2018 |
|
L:
A: |
English
Burden of illness, Cost of illness, |
|
|
| |
| |
| Feasibility Assessment for Conducting a Multi-Country Post-Marketing Safety Oncology Study Using Secondary Data Sources in Europe |
| Author(s): Wells KE, Jiang R, Tyczynski JE, Secrest M, Oliveria SA |
| Affiliations(s): Wells KE: IQVIA; Jiang R: Abbvie; Tyczynski JE: Abbvie; Secrest M: IQVIA; Oliveria SA: IQVIA |
Publication(s): 34th International Conference on Pharmacoepidemiology & Therapeutic Risk Management
|
| Document Type(s): Abstract, |
| Countries: Denmark, Finland, Germany, Norway, Sweden, UK, |
C:
Y: |
Database Validity and methodology, Oncology, Patient Registries & Real-World Study Methods,
2018 |
|
L:
A: |
English
Database Study, Epidemiological study, Retrospective cohort analysis, Retrospective database analysis, Review, |
|
|
| |
| |
| Different patterns of second?line treatment in type 2 diabetes after metformin monotherapy in Denmark, Finland, Norway and Sweden (D360 Nordic): A multinational observational study
|
| Author(s): Persson F, Bodegard J, Lahtela JT, Nyström T, Jørgensen ME, Jensen ML, Gulseth HL, Thuresson M, Hoti F, Nathanson D, Norhammar A, Birkeland KI, Eriksson JG, Eriksson JW
|
| Affiliations(s): StatFinn & EPID Research, Espoo, Finland
|
Publication(s): Endocrinol Diabetes Metab.
|
| Document Type(s): Article, |
| Countries: Denmark, Finland, Nordic, Norway, Sweden, |
| Click here for the abstract |
C:
Y: |
Diabetes,
2018 |
|
L:
A: |
English
Population Based Study, Retrospective database analysis, |
|
|
| |
| |
| Predictors of Overall Survival for Multiple Myeloma Patients Depending on Transplant Status According to a Retrospective, Non-Interventional Study in Norway |
| Author(s): Fredrik H. Schjesvold, MD PhD, Anderson Jenna, Jaak Sõnajalg, Amy Leval, PhD, Anna Lysén, MSc, Saeeda Rana, Päivi Castren-Kortekangas, Fredrik Borgsten |
| Affiliations(s): Fredrik H. Schjesvold - Oslo University; Jenna Anderson - EPID Research (now part of IQVIA); Jaak Sõnajalg - EPID Research (now part of IQVIA). |
Publication(s): Blood (2018) 132 (Supplement 1): 5759.
|
| Document Type(s): Abstract, |
| Countries: Norway, |
| Click here for the abstract |
C:
Y: |
Oncology,
2018 |
|
L:
A: |
English
Observational study, Population Based Study, |
|
|
| |
| |
| COMMONALITIES AND DIFFERENCES IN DATA COLLECTION ACROSS EUROPEAN SPONDYLOARTHRITIS REGISTRIES |
| Author(s): M. L. Hetland* 1, M. Østergaard1, J. Askling2, C. Gabay3, D. Nordstrom4, O. FitzGerald5, M. Hernández Miguel6, M. Santos7
, Z. Rotar8, H. Mann9, F. Iannone10, M. J. Nissen3, E. Hauge1, J. Gomez-Reino11, F. Díaz-González12, M. Tomsic8, K.
Pavelka9, F. O'Shea5, C. Sullivan5, M. van de Sande13, I. E. van der Horst-Bruinsma13, G. J. Macfarlane14, G. T. Jones14,
B. Gudbjørnsson15, T. K. Kvien16 on behalf of EuroSpA Study Group |
| Affiliations(s): 1DANBIO, Glostrup, Denmark, 2ARTIS, Stockholm, Sweden, 3SCQM, Geneva, Switzerland, 4ROB-FIN, Helsinki, Finland, 5ASRI, Dublin, Ireland, 6BIOBADASER, Barcelona, Spain, 7reuma.pt, Almada, Portugal, 8biorx.si, Ljubljana, Slovenia, 9ATTRA, Prague, Czech Republic, 10GISEA, Bari, Italy, 11BIOBADASER, Santiago, 12BIOBADASER, Santa Cruz de Tenerife, Spain, 13ARC, Amsterdam, Netherlands, 14BSRBR-AS, Aberdeen, United Kingdom, 15ICEBIO, Reykjavik, Iceland, 16NORDMARD, Oslo, Norway |
Publication(s): EULAR, Madrid, 2017
|
| Document Type(s): Abstract, |
| Countries: Czech, Denmark, Finland, Ireland, Italy, Norway, Slovenia, Spain, Sweden, Switzerland, |
| Click here for the abstract |
C:
Y: |
Rheumatology,
2017 |
|
L:
A: |
English
Epidemiological study, |
|
|
| |
| |
 1 of 2 
|
|
